Related Experiment Video
Updated: Aug 1, 2026
08:58
En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
Published on: February 25, 2016
Nitric oxide/L-arginine in uremia.
1Mario Negri Institute for Pharmacological Research, Bergamo, Slovakia.
Mineral and Electrolyte Metabolism
|February 22, 2000
Summary
Kidney disease progression involves abnormal nitric oxide (NO) pathways. Reduced NO in kidneys correlates with damage, while systemic NO increases in uremia, potentially as a defense against hypertension.
Area of Science:
- Nephrology
- Cardiovascular Physiology
- Biochemistry
Background:
- Nitric oxide (NO) regulates vascular tone and platelet function.
- Abnormalities in NO synthesis are implicated in renal disease progression.
- Both reduced renal NO and increased systemic NO are observed in kidney disease models.
Purpose of the Study:
- To investigate the role of NO synthesis abnormalities in renal disease.
- To explore the relationship between NO, endothelin-1, and renal damage.
- To understand the mechanisms of altered NO production in uremia.
Main Methods:
- Experimental model of renal mass reduction (RMR) in rats.
- Analysis of inducible NO synthase (iNOS) and endothelial NOS (eNOS) expression.
- In vitro and in vivo studies on endothelin-1 (ET-1) and guanidinosuccinate effects.
Main Results:
- Rats with RMR showed reduced kidney NO production, correlating with renal damage.
- Progressive iNOS loss in RMR rats may be linked to increased renal endothelin-1 (ET-1).
- Uremic rats and patients exhibited excessive systemic NO release, linked to iNOS and eNOS upregulation.
Conclusions:
- NO pathway dysregulation is central to hemodynamic and hemostatic disorders in renal disease.
- Increased renal ET-1 may contribute to iNOS deficiency in RMR.
- Elevated systemic NO in uremia might be a compensatory mechanism against hypertension but could exacerbate bleeding risks.
Related Concept Videos
01:23Urea Cycle
The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
01:202° Amines to N-Nitrosamines: Reaction with NaNO2
Secondary amines react with nitrous acid to form N-nitrosamines, as depicted in Figure 1. Nitrous acid, a weak and unstable acid, is formed in situ from an aqueous solution of sodium nitrite and strong acids, such as hydrochloric acid or sulfuric acid, in cold conditions. In the presence of an acid, the nitrous acid gets protonated. The subsequent loss of water results in the formation of the electrophile known as nitrosonium ion.
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:24Serum Studies: Renal Function Tests
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.